Home/Filings/4/0001209191-18-010564
4//SEC Filing

Harland John M 4

Accession 0001209191-18-010564

CIK 0000072444other

Filed

Feb 14, 7:00 PM ET

Accepted

Feb 15, 8:18 PM ET

Size

15.6 KB

Accession

0001209191-18-010564

Insider Transaction Report

Form 4
Period: 2018-02-13
Harland John M
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2018-02-13+9,5639,563 total
    Exercise: $8.03Exp: 2024-05-08Common Stock (9,563 underlying)
  • Award

    Stock Option (right to buy)

    2018-02-13+4,0874,087 total
    Exercise: $12.98Exp: 2026-03-25Common Stock (4,087 underlying)
  • Award

    Stock Option (right to buy)

    2018-02-13+8,2558,255 total
    Exercise: $17.49Exp: 2025-07-23Common Stock (8,255 underlying)
  • Award

    Stock Option (right to buy)

    2018-02-13+7,0477,047 total
    Exercise: $4.07Exp: 2027-06-24Common Stock (7,047 underlying)
Footnotes (5)
  • [F1]Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split").
  • [F2]On May 8, 2014, Reporting Person was granted an option to purchase 475,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,563 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $8.03 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of March 24, 2014 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
  • [F3]On July 23, 2015, Reporting Person was granted an option to purchase 410,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.35 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 8,255 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $17.49 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 30, 2015 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
  • [F4]On March 25, 2016, Reporting Person was granted an option to purchase 203,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.26 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 4,087 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $12.98 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of March 24, 2016 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.
  • [F5]On June 24, 2017, Reporting Person was granted an option to purchase 350,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.08 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,047 shares of the Issuer's common stock (as adjusted for Stock Split) at a per share exercise price of $4.07 (as adjusted for Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 14, 2017 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter.

Issuer

Vaxart, Inc.

CIK 0000072444

Entity typeother

Related Parties

1
  • filerCIK 0001546788

Filing Metadata

Form type
4
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 8:18 PM ET
Size
15.6 KB